{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125361","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.130988+00:00","generated_at":"2026-05-30T01:59:44.049197+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Crinetics reports Q3 net loss $76.8M; submits NDA for paltusotine; raises $575M","bullets":["Net loss of $76.8M in Q3 2024 vs $57.5M in Q3 2023; revenue $0 vs $0.3M from SKK licensing.","NDA submitted for paltusotine (oral somatostatin agonist) for acromegaly; FDA decision expected Dec 2024.","Upsized public offering raised $575M gross; pro-forma cash ~$1.4B, funding operations into 2029.","Four candidates in IND-enabling studies; first NDC platform candidate data at NANETS Nov 2024; TSH antagonist IND expected 2025.","R&D expenses $61.9M (+41% YoY); G&A $25.9M (+67% YoY), driven by pipeline expansion and launch prep."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125361","json":"https://secwatch.observer/filing/0000950170-24-125361.json","markdown":"https://secwatch.observer/filing/0000950170-24-125361.md","text":"https://secwatch.observer/filing/0000950170-24-125361.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024125361/0000950170-24-125361-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024125361/crnx-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:59:44.049197+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}